Aerie Pharmaceuticals (NASDAQ:AERI) and Spark Therapeutics (NASDAQ:ONCE) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, earnings, risk, valuation and dividends.
This is a summary of current recommendations and price targets for Aerie Pharmaceuticals and Spark Therapeutics, as reported by MarketBeat.com.
||Strong Buy Ratings
Aerie Pharmaceuticals presently has a consensus target price of $81.00, suggesting a potential upside of 103.11%. Spark Therapeutics has a consensus target price of $66.55, suggesting a potential upside of 60.52%. Given Aerie Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Aerie Pharmaceuticals is more favorable than Spark Therapeutics.
Valuation and Earnings
This table compares Aerie Pharmaceuticals and Spark Therapeutics’ revenue, earnings per share (EPS) and valuation.
||Earnings Per Share
Aerie Pharmaceuticals has higher earnings, but lower revenue than Spark Therapeutics. Aerie Pharmaceuticals is trading at a lower price-to-earnings ratio than Spark Therapeutics, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Aerie Pharmaceuticals has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500. Comparatively, Spark Therapeutics has a beta of 2.25, indicating that its share price is 125% more volatile than the S&P 500.
This table compares Aerie Pharmaceuticals and Spark Therapeutics’ net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
Spark Therapeutics beats Aerie Pharmaceuticals on 6 of the 11 factors compared between the two stocks.
Aerie Pharmaceuticals Company Profile
Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. The company's advanced-stage product candidate is Roclatan, a once-daily eye drop to reduce IOP to treat patients with open-angle glaucoma and ocular hypertension. Aerie Pharmaceuticals, Inc. has a collaborative research, development, and licensing agreement with DSM. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Durham, North Carolina.
Spark Therapeutics Company Profile
Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec), which is in Phase III clinical trial for the treatment of genetic blinding conditions caused by mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia. The company's products also comprise SPK-7001 that is in Phase 1/2 trial for choroideremia; SPK-9001, which is in Phase 1/2 trial for hemophilia B; and SPK-8011 that is in Phase 1/2 trial hemophilia A. In addition, its product candidates and development programs include SPK-FVIII program to treat hemophilia A; SPK-TPP1 program for the treatment of CLN2 disease; RhoNova for the treatment of rhodopsin-linked autosomal dominant retinitis pigmentosa; and other neurodegenerative diseases. The company has collaboration agreement with Pfizer, Inc. for the development and commercialization of SPK-FIX product candidates in its gene therapy program for the treatment of hemophilia B. Spark Therapeutics, Inc. was founded in 2013 and is headquartered in Philadelphia, Pennsylvania.
Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.